A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
RET Proto-Oncogene, Full Gene Analysis
Message*Draw Monday-Thursday before 2:30pm. Do not collect on weekends or holidays.
Test Code
LAB00460
Alias/See Also
LAB00460
Mayo TC: RETZZ
Mayo Test Name: Multiple Endocrine Neoplasia Type 2 Syndrome, RET, Full Gene Analysis, Varies
Mayo TC: RETZZ
Mayo Test Name: Multiple Endocrine Neoplasia Type 2 Syndrome, RET, Full Gene Analysis, Varies
CPT Codes
81406
Physician Attestation of Informed Consent
Providers: Informed consent and education are required prior to drawing specimen! Please see Instructions below.
Preferred Specimen
3.0 mL Lavender (EDTA) - Whole Blood
Minimum Volume
1.0 mL Lavender (EDTA) - Whole Blood
Other Acceptable Specimens
Yellow Top (ACD) - Whole Blood
Instructions
REQUIRES ORDER FORM T729 AND ADDITIONAL INFORMATION FORM T576 SENT TO MAYO
https://www.mayocliniclabs.com/it-mmfiles/MC1235-97_Molecular_Genetics-Congenital_Inherited_Diseases_Patient_Information.pdf
https://www.mayocliniclabs.com/it-mmfiles/Informed_Consent_for_Genetic_Testing.pdf
https://www.mayocliniclabs.com/it-mmfiles/MC1235-97_Molecular_Genetics-Congenital_Inherited_Diseases_Patient_Information.pdf
https://www.mayocliniclabs.com/it-mmfiles/Informed_Consent_for_Genetic_Testing.pdf
Transport Temperature
Room Temperature
Specimen Stability
Room Temperature: 4 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.
Methodology
Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing
Report Available
21-28 days
Clinical Significance
Evaluating patients with a personal or family history suggestive of a multiple endocrine neoplasia type 2 (MEN2) or Hirschsprung disease (HSCR).
Establishing a diagnosis of MEN2 or HSCR allowing for targeted cancer surveillance based on associated risks.
Identifying varients within genes known to be associated with MEN2 or HSCR allowing for predictive testing of at-risk family members.
Establishing a diagnosis of MEN2 or HSCR allowing for targeted cancer surveillance based on associated risks.
Identifying varients within genes known to be associated with MEN2 or HSCR allowing for predictive testing of at-risk family members.
Performing Laboratory
Mayo Clinic